BioCentury | Dec 6, 2010
Financial News

SuppreMol completes venture financing

...€15.5 million ($20.6 million) Investors: MIG Verwaltungs AG; BioMedPartners; Santo Holding; KFW Mittelstandsbank; Bayern Kapital; Max Planck Gesellschaft...
BioCentury | Dec 2, 2010
Financial News

SuppreMol adds EUR 15.5 million in C round

SuppreMol GmbH (Martinsried, Germany) raised EUR 15.5 million ($20.6 million) in a series C round led by existing investors MIG and BioMedPartners. New investor FCP Biotech Holding joined existing investors Santo Holding; KfW Mittelstandsbank; Bayern...
BioCentury | Dec 4, 2000
Company News

GPC Biotech, California Institute of Technology, Max-Planck-Gesellschaft deal

GPC received from Cal Tech and Max-Planck's Garching Innovation licensing agent a license to intellectual property covering Detection Enhanced Ubiquitin Split Protein Sensor (DEUS-PS), a protein-protein interaction technology for molecular pathway mapping. GPC Biotech AG...
BioCentury | Dec 4, 2000
Finance

Trailing indicator

Biotech somehow still is managing to avoid the hammering put on the broader NASDAQ market. Although the BioCentury 100 is down 4 percent over the last two weeks and stands down 19 percent since the...
BioCentury | Feb 22, 1999
Company News

Artemis, Max Planck Institute for Developmental Biology deal

...agreement. If the option is exercised, Artemis would pay royalties to the Institute's parent organization, Max Planck Gesellschaft...
Items per page:
1 - 5 of 5
BioCentury | Dec 6, 2010
Financial News

SuppreMol completes venture financing

...€15.5 million ($20.6 million) Investors: MIG Verwaltungs AG; BioMedPartners; Santo Holding; KFW Mittelstandsbank; Bayern Kapital; Max Planck Gesellschaft...
BioCentury | Dec 2, 2010
Financial News

SuppreMol adds EUR 15.5 million in C round

SuppreMol GmbH (Martinsried, Germany) raised EUR 15.5 million ($20.6 million) in a series C round led by existing investors MIG and BioMedPartners. New investor FCP Biotech Holding joined existing investors Santo Holding; KfW Mittelstandsbank; Bayern...
BioCentury | Dec 4, 2000
Company News

GPC Biotech, California Institute of Technology, Max-Planck-Gesellschaft deal

GPC received from Cal Tech and Max-Planck's Garching Innovation licensing agent a license to intellectual property covering Detection Enhanced Ubiquitin Split Protein Sensor (DEUS-PS), a protein-protein interaction technology for molecular pathway mapping. GPC Biotech AG...
BioCentury | Dec 4, 2000
Finance

Trailing indicator

Biotech somehow still is managing to avoid the hammering put on the broader NASDAQ market. Although the BioCentury 100 is down 4 percent over the last two weeks and stands down 19 percent since the...
BioCentury | Feb 22, 1999
Company News

Artemis, Max Planck Institute for Developmental Biology deal

...agreement. If the option is exercised, Artemis would pay royalties to the Institute's parent organization, Max Planck Gesellschaft...
Items per page:
1 - 5 of 5